| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jeremy Danie. Cannabidiol for the Treatment of Pediatric Epilepsy. Pediatric annals. vol 52. issue 10. 2023-10-11. PMID:37820705. |
this article seeks to provide a pathophysiological basis for cannabidiol in epilepsy, discuss commercially available products and nonpharmaceutical marijuana, and review recent evidence in pediatric epilepsy. |
2023-10-11 |
2023-10-15 |
Not clear |
| M Perriguey, M El Succar, A Clément, S Lagarde, O Ribes, X Dode, S Rheims, F Bartolome. High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies. Revue neurologique. 2023-10-08. PMID:37806886. |
high-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies. |
2023-10-08 |
2023-10-15 |
Not clear |
| Shampa Ghosh, Jitendra Kumar Sinha, Soumya Ghosh, Hitaishi Sharma, Rakesh Bhaskar, Kannan Badri Narayana. A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. Brain sciences. vol 13. issue 9. 2023-09-28. PMID:37759906. |
insights into cannabidiol (cbd) and the ketogenic diet as adjunctive therapies further broaden the spectrum of epilepsy management. |
2023-09-28 |
2023-10-07 |
Not clear |
| Josiah Damisa, Alexandra Petohazi, Hassan Jalil, Michelle Richardso. Is Cannabis Effective in the Treatment of Chronic Back Pain? Cureus. vol 15. issue 8. 2023-09-11. PMID:37692601. |
in the united kingdom, cannabis has been recognized and licensed for medical use since november 2018, with about 12 national health service prescriptions in circulation largely due to patient pressure, with support from media campaigns for its use when there was growing evidence of its use in intractable epilepsy. |
2023-09-11 |
2023-10-07 |
Not clear |
| G Ferrera, E Ricci, A Vignoli, M N Savini, I Viganò, V Chiesa, D Caputo, E Zambrelli, F La Briola, K Turner, M P Canevin. Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center. Epilepsy & behavior : E&B. vol 147. 2023-09-07. PMID:37677907. |
highly purified cannabidiol in the treatment of drug-resistant epilepsies: a real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single italian center. |
2023-09-07 |
2023-10-07 |
Not clear |
| G Ferrera, E Ricci, A Vignoli, M N Savini, I Viganò, V Chiesa, D Caputo, E Zambrelli, F La Briola, K Turner, M P Canevin. Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center. Epilepsy & behavior : E&B. vol 147. 2023-09-07. PMID:37677907. |
seizure frequency in treatment-resistant epilepsies seems to be decreased by cannabidiol (cbd), but contrasting data are available on its effect on sleep, behavior, and quality of life (qol), and no data is reported on its effect on parental stress in patients with epilepsy (pwe). |
2023-09-07 |
2023-10-07 |
Not clear |
| Ioannis Karaki. Adjunctive Use of Cannabidiol: A Joint Action to Patch Up Drug-Resistant Epilepsy. Epilepsy currents. vol 23. issue 4. 2023-09-04. PMID:37662455. |
adjunctive use of cannabidiol: a joint action to patch up drug-resistant epilepsy. |
2023-09-04 |
2023-09-07 |
Not clear |
| Xiuli Wang, Huanbang Zhang, Yan Liu, Yang Xu, Bingyou Yang, Hua Li, Lixia Che. An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives. Bioorganic chemistry. vol 140. 2023-09-02. PMID:37659147. |
currently, epidiolex (cannabidiol) has been approved by the fda for the treatment of two rare and severe forms of epilepsy related diseases, namely lennox-gastaut syndrome (lgs) and dravet (ds). |
2023-09-02 |
2023-09-07 |
Not clear |
| Epilepsy and cannabis: So near, yet so far. Developmental medicine and child neurology. 2023-08-18. PMID:37592390. |
epilepsy and cannabis: so near, yet so far. |
2023-08-18 |
2023-09-07 |
Not clear |
| Vicino Walter, Muccioli Lorenzo, Pondrelli Federica, Licchetta Laura, Stipa Carlotta, Mostacci Barbara, Di Vito Lidia, Ferri Lorenzo, Cancellerini Chiara, Soldà Martina, Tinuper Paolo, Bisulli Francesc. Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy. Seizure. vol 111. 2023-07-28. PMID:37506564. |
real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy. |
2023-07-28 |
2023-08-14 |
Not clear |
| Vicino Walter, Muccioli Lorenzo, Pondrelli Federica, Licchetta Laura, Stipa Carlotta, Mostacci Barbara, Di Vito Lidia, Ferri Lorenzo, Cancellerini Chiara, Soldà Martina, Tinuper Paolo, Bisulli Francesc. Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy. Seizure. vol 111. 2023-07-28. PMID:37506564. |
to evaluate the efficacy and safety of cannabidiol (cbd) for the treatment of epilepsy in a real-world setting. |
2023-07-28 |
2023-08-14 |
Not clear |
| Béatrice Desnous, Thibault Beretti, Nathan Muller, Julien Neveu, Nathalie Villeneuve, Anne Lépine, Géraldine Daquin, Mathieu Mil. Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome. Epilepsia open. 2023-07-24. PMID:37485779. |
efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with rett syndrome. |
2023-07-24 |
2023-08-14 |
Not clear |
| Béatrice Desnous, Thibault Beretti, Nathan Muller, Julien Neveu, Nathalie Villeneuve, Anne Lépine, Géraldine Daquin, Mathieu Mil. Efficacy and tolerance of cannabidiol in the treatment of epilepsy in patients with Rett syndrome. Epilepsia open. 2023-07-24. PMID:37485779. |
we aim to assess the efficacy and tolerance of cannabidiol as adjunctive therapy for rett syndrome (rtt) patients with epilepsy. |
2023-07-24 |
2023-08-14 |
Not clear |
| Seyyed Reza Ebadi, Kiarash Saleki, Tanin Adl Parvar, Negin Rahimi, Vajiheh Aghamollaii, Sara Ranji, Abbas Tafakhor. The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial. Frontiers in neurology. vol 14. 2023-07-20. PMID:37470002. |
the effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial. |
2023-07-20 |
2023-08-14 |
Not clear |
| Seyyed Reza Ebadi, Kiarash Saleki, Tanin Adl Parvar, Negin Rahimi, Vajiheh Aghamollaii, Sara Ranji, Abbas Tafakhor. The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial. Frontiers in neurology. vol 14. 2023-07-20. PMID:37470002. |
recent research showed the efficacy of add-on therapy by cannabidiol (cbd) on refractory epilepsy. |
2023-07-20 |
2023-08-14 |
Not clear |
| Mona Heiland, Niamh M C Connolly, Omar Mamad, Ngoc T Nguyen, Jaideep C Kesavan, Elena Langa, Kevin Fanning, Albert Sanfeliu, Yan Yan, Junyi Su, Morten T Venø, Lara S Costard, Valentin Neubert, Tobias Engel, Thomas D M Hill, Thomas M Freiman, Arun Mahesh, Vijay K Tiwari, Felix Rosenow, Sebastian Bauer, Jørgen Kjems, Gareth Morris, David C Henshal. MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure control. Proceedings of the National Academy of Sciences of the United States of America. vol 120. issue 30. 2023-07-18. PMID:37463203. |
here we show that genome-wide mirna screening of hippocampal tissue from a rat epilepsy model, mice treated with the antiseizure medicine cannabidiol, and plasma from patients with treatment-resistant epilepsy, converge on a single target-mir-335-5p. |
2023-07-18 |
2023-08-14 |
mouse |
| Nicolás Fernández, Marcello Gian Cappello, Patricia Noemí Quirog. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina. Forensic science international. vol 349. 2023-07-01. PMID:37392612. |
in recent years, the therapeutic use of cannabis products, especially cannabis oils, has increased significantly, due to the pharmacological potential of their cannabinoids, for the treatment of conditions, such as pain management, cancer, and epilepsy. |
2023-07-01 |
2023-08-14 |
Not clear |
| Jian Huang, Xiao Fan, Xueqin Jin, Sooyeon Jo, Hanxiong Bear Zhang, Akie Fujita, Bruce P Bean, Nieng Ya. Cannabidiol inhibits Na Nature communications. vol 14. issue 1. 2023-06-17. PMID:37330538. |
cannabidiol inhibits na cannabidiol (cbd), a major non-psychoactive phytocannabinoid in cannabis, is an effective treatment for some forms of epilepsy and pain. |
2023-06-17 |
2023-08-14 |
Not clear |
| Tom Jukier, Crisanta Cruz-Espindola, Doug Martin, Dawn M Booth. Disposition of a single oral dose of a cannabidiol medication in healthy cats. Frontiers in veterinary science. vol 10. 2023-06-12. PMID:37303724. |
recently, the food and drug administration has approved a highly purified cannabidiol medication for the add on therapy in people with certain forms of epilepsy. |
2023-06-12 |
2023-08-14 |
Not clear |
| Caroline Esmonde-White, Richard S McLachlan, Jorge Burneo, Jayme Arts, Carmela Redhead, Ana Suller Mart. Nationwide Study of Postlegalization Marijuana Use Among Patients With Epilepsy in Canada. Neurology. Clinical practice. vol 13. issue 4. 2023-05-30. PMID:37251367. |
it was established before the legalization of marijuana in canada in 2018 that many patients with epilepsy use marijuana to treat their seizures or for recreational purposes. |
2023-05-30 |
2023-08-14 |
Not clear |